Study of a new drug for advanced colorectal cancer with KRAS G12D mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug (BAY 3771249) for people with advanced or metastatic colorectal cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and if it can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced or metastatic colorectal cancer (adenocarcinoma) that has spread or cannot be removed by surgery.
- Your tumor must have a specific genetic change called KRAS G12D.
- You must have at least one tumor that can be measured on a scan (outside the brain).
- You should be generally active and able to care for yourself (ECOG performance status 0 or 1).
- You must not have certain untreated brain metastases, active infections (like HIV, hepatitis B or C), or significant heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
This trial tests three drugs (adagrasib, cetuximab, cemiplimab) together for colorectal cancer with a KRAS G12C mutation. The goal is to see if this combination shrinks tumors or slows cancer growth.
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
This trial is testing a combination of two targeted drugs (panitumumab and sotorasib) with a chemotherapy drug (5-fluorouracil) for people with advanced colorectal cancer that has a specific KRAS G12C mutation and who cannot receive stronger chemotherapy. It aims to see if this treatment can help control the cancer.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
Hear when a new Advanced/Metastatic Colorectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.